Objectives Reports of increased amyotrophic lateral sclerosis (ALS) with hyperlipidaemia and elevated plasma homocysteine levels as well as cigarette-smoking and polymorphisms in angiogenic genes suggest a role for altered vascular homeostasis in ALS pathogenesis. The authors assessed the association between vascular risk factors and ALS.
Methods Traditional cardiovascular risk factors (smoking, hypertension, hypercholesterolaemia, diabetes and body mass index (BMI)) and cardiovascular disease prior to ALS onset established by a questionnaire were compared in 334 patients and 538 age- and sex-matched controls. Biochemical assessments (total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), hs-CRP, and homocysteine) at diagnosis were measured in blood samples of 303 patients with ALS and compared with prospectively collected data from 2100 population-based controls.
Results Patients with ALS used cholesterol-lowering agents less frequently (OR=0.6, p=0.008) and had a lower BMI (OR=0.9, p=0.001), a lower LDL/HDL ratio (women: OR=0.5, p<0.001; men: OR=0.4, p<0.001) and lower homocysteine levels (women: OR=0.9, p=0.02; men: OR=0.9, p<0.001). The mean LDL and TC levels were significantly lower among patients with a lower functional vital capacity percentage of predicted (FVC). In the univariate analysis, a higher LDL/HDL ratio correlated with increased survival (HR=0.9, p=0.04); after adjusting for the confounders age, site and FVC, no difference was observed.
Conclusions Vascular risk factors, measured clinically and biochemically, were not associated with increased ALS. Instead, patients reported less use of cholesterol-lowering medication and had a lower premorbid BMI and favourable lipid profile—all findings consistent with the hypothesis that a higher metabolic rate plays a role in ALS.
- Motor neuron disease
Statistics from Altmetric.com
Studies on angiogenic factors have suggested a role for altered vascular homeostasis in amyotrophic lateral sclerosis (ALS) pathogenesis. In several human populations, vascular endothelial growth factor (VEGF) haplotypes associated with low VEGF levels are more prevalent among ALS patients, and mice expressing reduced VEGF levels develop motor neuron degeneration.1–3 Moreover, the functionally similar angiogenin has been associated with ALS.4–6 Vasculature damage may be an early pathological event leading to motor neuron degeneration in the transgenic mutated SOD1 mouse model of ALS.7
Findings have suggested vascular risk factors to contribute to neurodegeneration in Alzheimer's disease.8–11 Only one study examined the presence of multiple vascular risk factors in ALS patients12 but remained inconclusive owing to a small study size. Other studies have focused on blood levels of specific vascular parameters: reports of higher plasma homocysteine13 and higher lipid14 levels seem to suggest atherogenic risk factors in ALS; however, the lack of association between lipid levels and ALS in a more recent study was not able to reinforce this hypothesis.15 Moreover, the implication of the protective effect of higher lipid levels on disease progression found in one study,14 but not in another study,15 requires further elucidation. These different results have been suggested to be partly explained by an association of lower lipid status with lower respiratory function.15
The aim of the present study was to assess the hypothesis that a higher risk profile for vascular disease, measured by clinical and biochemical indicators, was associated with susceptibility for developing ALS and to assess the association with survival in patients, after adjusting for confounders.
Between 1 July 2004 and 1 July 2009, patients diagnosed as having sporadic ALS at the University Medical Centre Utrecht, a tertiary referral clinic in The Netherlands, were recruited. Diagnosis was made according to the El Escorial Criteria after exclusion of other conditions. Patients diagnosed as having possible, probable or definite ALS according to the El Escorial criteria were included. The age and site of onset of disease were recorded. The onset of disease was defined as the time of initial weakness, dysarthria or dysphagia. The study protocol was approved by the institutional ethical committee of the University Medical Centre Utrecht.
In the questionnaire study, 334 patients and 538 controls were included. Controls were derived from two sources. Each case was asked to approach an individual meeting the following criteria: (1) not a spouse, partner, or blood relative; (2) age difference of 5 years or less; (3) same sex. Also, the general practitioner of the patient was asked to select a control randomly from his clinic meeting the same criteria.
Demographic characteristics (age, sex, level of education), and the occurrence of traditional vascular risk factors and disease were ascertained by a questionnaire. Hypertension, hypercholesterolaemia and diabetes were classified as present when the use of disease-specific medication was reported. Data on cigarette-smoking habits, height and weight during adulthood were collected. Body mass index (BMI) was calculated, and overweight was defined as BMI≥25 kg/m2. In patients with ALS, only data referring to the period before the onset of first symptoms were analysed. The occurrence of vascular disease was ascertained by questions relating to ever having had a myocardial infarction, angina pectoris, stroke and transient ischaemic attacks, or peripheral bypass or angioplasty (peripheral vascular disease).
Blood sample study
In the blood sample study, 303 patients and 2100 controls were included. There is some overlap between the two patient cohorts from the questionnaire and blood-sample studies. Both cohorts are derived from the same source patient population (tertiary referral centre). In both cohorts, patients were sampled for inclusion. Controls were recruited from participants enrolled in two prospective studies in The Netherlands described elsewhere.16–18 The Hormonal changes in the Ageing MaLe and Epidemiological Taskforce (HAMLET) study was a single-centre, population-based cohort study in 400 men, aged 40–80 years, who lived independently. It was designed to explore vascular risk factors.16 17 Volunteers were recruited by means of invitation letters to a random sample of the municipal register of Utrecht and a database of potential volunteers nominated by volunteers of previous studies. The Prospect-EPIC (European Prospective Investigation into Cancer and nutrition) study was a population-based cohort study of 17 357 healthy women aged 50–70 recruited from breast-cancer-screening participants designed to assess the relation between nutrition and cancer.18 From this EPIC cohort, 1700 women were randomly sampled for blood analysis.
Total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and its derived total LDL/HDL ratio, high sensitive (hs)-CRP and homocysteine, have been shown to be independently associated with other vascular risk factors and disease. Non-fasting blood samples from patients with ALS at the time of diagnosis, non-fasting blood samples from Prospect-controls and fasting blood samples from HAMLET controls were collected. TC, LDL, HDL, glucose and hs-CRP were measured in all participants of Prospect (n=1700) and HAMLET (n=400). Homocysteine was measured in all (n=400) HAMLET and in a subset of the Prospect subjects (n=950). TC, LDL, HDL and homocysteine in plasma were measured using an enzymatic assay.19 Hs-CRP was measured in serum in patients and HAMLET control subjects. We adjusted for the plasma measurements of hs-CRP in the Prospect study by multiplying all values by 1.13. Details of the measurements are provided elsewhere.17 19–21
The functional vital capacity percentage of predicted (FVC) was measured in all patients at the time of blood sampling.
We compared the prevalence of measures of cardiovascular risk in the ALS group with that of the control group. To determine whether ALS was associated with self-reported cardiovascular risk factors and events, a logistic regression analysis was performed. In order to determine the increase in ALS risk with each unit of increment in serum values, a logistic regression analysis adjusting for age was performed for women and men separately, because the age and sex distribution differed among patients and controls.
FVC is known to be associated with survival. To assess this possible confounder in the survival analysis, the association between FVC and lipid levels was tested by linear regression. To determine whether survival was associated with self-reported cardiovascular risk factors and events, and blood levels of vascular risk factors, a univariate Cox regression and a multivariate Cox regression were performed, adjusting for age, site at onset and FVC at the time of blood sampling, confounders significantly associated with survival. To determine whether serum values were influenced by the duration of disease in patients with ALS, linear regression was used to study the association between blood levels and onset-diagnosis interval. A two-sided p value of <0.05 was considered significant. The study protocol was approved by the institutional ethical committee of the University Medical Centre Utrecht. All patients gave informed consent prior to the study.
Tables 1, 2 show the characteristics of 334 patients and 538 controls in the questionnaire study (table 1) and 303 patients (131 women and 172 men) and 2100 controls (1700 women and 400 men) in the blood sample study (table 2). In ALS patients, the age and site at onset were similar to those reported in previous population-based studies.22 The response rate of the participants in the questionnaire study was 80%. The characteristics of patients with ALS who completed questionnaires did not differ from those of patients with ALS for whom blood samples were available. The patient characteristics of participants and non-participants were similar. In the questionnaire study, sex and age were similar among patients and controls. In the blood-sample study, patients were significantly older, and there were more men than in the control population; therefore, we adjusted for these confounders.
Vascular risk factors and ALS
Table 3 shows the frequency of self-reported vascular risk factors in patients and controls. Compared with controls, fewer patients used cholesterol-lowering agents (OR=0.6, 95% CI 0.4 to 0.9, p=0.008) or were overweight (OR=0.7, 95% CI 0.5 to 1.0, p=0.02); moreover, patients had a lower BMI (OR=0.9, 95% CI 0.9 to 1.0, p=0.001).
Table 4 shows the blood levels of biochemical indicators of vascular risk in patients and controls. All lipid values were consistent with lower vascular risk in patients: TC and LDL were significantly lower, and HDL was significantly higher. The LDL/HDL ratio was significantly lower in patients with ALS (in women, OR=0.4, 95% CI 0.3 to 0.6, p<0.001; in men, OR=0.5, 95% CI 0.4 to 0.6, p<0.001). The lipid profile in patients who completed the questionnaire did not differ significantly from those who did not complete questionnaires.
Significantly lower homocysteine levels were found in patients with ALS (in women: OR=0.9, 95% CI 0.9 to 1.0, p=0.02; in men: OR=0.9, 95% CI 0.8 to 0.9, p<0.001). No significant associations between hs-CRP levels and ALS status were observed. Stratification for disease duration did not show any differences in measured blood levels (data not shown).
Cholesterol levels and survival in ALS
FVC and site at onset are known to be associated with survival. In patients with ALS, the mean FVC was 87%. Table 5 shows the lipid status according to respiratory function at the time of blood sampling. The mean LDL- and TC levels were significantly lower among patients with a lower FVC. Endpoints (ie, death) were reached in 207 out of 331 patients with ALS in the questionnaire study. The median survival was 3.5 years. In the blood-sample study, endpoints were reached in 101 of 131 female patients with ALS and 124 of 172 male patients. The median survival was 2.6 years (in women as well as in men). A Univariate Cox regression showed a significantly increased survival for patients with a high LDL/HDL ratio in the male (HR=0.8, p=0.01) and total group (HR=0.9, p=0.04) (table 6). This association disappeared in the multivariate Cox regression, after adjusting for age, site at onset and FVC (table 6).
The results of our clinical and biochemical studies were all consistent with a more favourable vascular risk profile in patients with ALS than in controls; besides having lower homocysteine levels, ALS patients used cholesterol-lowering agents less frequently, had a lower premorbid BMI and obesity rate, and had a more favourable lipid profile. The finding of a shorter survival for ALS patients with low lipid levels is in agreement with one previous study14 and suggests that a more favourable lipid profile is a risk factor as well as a disease-modifying factor in ALS. However, we also observed a significant association between low FVC and lower lipid levels, suggesting an increased energetic demand or inflammatory status owing to the increased respiratory effort.15 The significantly shorter survival of patients with a favourable lipid profile was no longer observed after adjusting for FVC, indicating that the effect of lipid levels on survival may be explained by this confounder. This may represent a state of debilitation in which poor FVC correlates with advanced disease and therefore poor nutrition. However, a causal effect of lipid levels on survival mediated by FVC cannot be excluded.
Only one previous study including 45 patients with ALS and 90 controls examined the presence of multiple vascular risk factors in ALS patients but was underpowered to detect an association between ALS and risk factors identified by chart review.12 The favourable lipid profile in patients with ALS in our study is in contrast to the reported higher14 or similar15 blood cholesterol levels observed in patients with ALS in previous studies. These apparent discrepancies may have been caused by differences in the control population. In one study,14 lipid levels in controls were lower than in our study, which could be explained by an under-representation of persons with high cholesterol levels in the control population owing to selection of health-conscious individuals, as they used as controls visitors for routine cholesterol work-up in the hospital after excluding those with disorders associated with vascular disease. In a more recent study,15 the lipid levels in the controls were lower than in our study, but controls taking lipid-lowering drugs and those with diabetes mellitus were excluded, which may have resulted in an under-representation of persons with a high vascular risk and high cholesterol levels.15
Consistent with an earlier report,23 our study showed an increased incidence of ALS among premorbid, leaner individuals, which has been linked to an increased metabolic rate in patients with ALS and in mouse models prior to disease onset.24–26 Resting energy expenditure is increased in patients with ALS. Also, a lower premorbid BMI has been previously found to be associated with ALS suggested to be a proxy for increased premorbid physical activity.23 These results therefore indicate that lipid profiles in ALS are a reflection of either increased premorbid physical activity or hypermetabolism. A recent review concludes that clinical and experimental studies have shown that abnormal energy homoeostasis has a role in ALS, and altered lipid levels have been put forward as an explanation for energy imbalance in ALS.27
Another previously studied biochemical indicator associated with vascular disease is homocysteine, which has atherogenic and prothrombotic properties.28 Our study in 303 patients and 1350 controls showed lower homocysteine levels among patients, in contrast to the increased fasting homocysteine levels in 62 patients with ALS compared with 88 controls in a previous study.13 Homocysteine levels may be influenced by vitamin B6 and B12 levels. However, as vitamin B deficiencies lead to hyperhomocysteinaemia, the corrected homocysteine levels in our patients would be even lower if they had vitamin B6 and B12 deficiencies. This factor does not, therefore, interfere with our conclusion that homocysteine levels in our patients are lower than in controls, and discrepancies between studies are most probably attributable to differences in control populations (outpatients in a tertiary clinic versus a prospective cohort in our study).
A consideration is that data for patients and controls in the blood sample study were ascertained in different ways. Non-fasting blood samples were collected from patients with ALS and from female controls, but fasting blood samples from male controls. This does not, however, explain the observed difference in levels of cholesterol and homocysteine between patients and controls; if results were influenced, we would expect an even larger difference in blood levels between patients and controls. Moreover, blood samples of patients were collected after the onset of disease, thus making a distinction between cause and consequence difficult. It would be interesting to go back into the patient records, well before the onset of ALS, to determine if the lipid markers were always in the favourable range. All blood samples were, however, collected at the first visit—usually a relatively early stage of the disease—and stratification for disease duration did not show any differences between samples taken at an early stage and at a late stage. Also, lipid controls were not age-matched, but we adjusted for this in our analyses.
In the questionnaire study, we took into account the onset of first weakness and only scored self-reported risk factors which occurred prior to disease onset. The finding of lower cholesterol levels in patients at diagnosis seems to agree with the data from self-reports of more frequent use of cholesterol-lowering agents and the low BMI preceding disease onset.
In the questionnaire study, a limitation is possible recall bias in the patient group. However, there was no indication of over-reporting vascular risk factors in the patient group. Also, using acquaintances as controls could have contributed to overmatching which would bias the risk estimate towards the null. If the results were influenced, we would expect an even stronger association between ALS and use of cholesterol-lowering medication. Moreover, the prevalence of vascular risk factors in our control group did not show any major differences compared with the figures reported for the Dutch population in the national registry. This suggests that the control group (which also consisted of population-based individuals randomly selected by the general practitioner) is representative of the general population.
The present study does not show cardiovascular risk factors and disease to be associated with ALS, but the association of ALS with a favourable lipid profile may support the hypothesis that an increased metabolism, as part of a complex genetic profile, independent of activity levels or diet, may play a role in the pathogenesis of ALS. Determining causation, however, requires more research.
We would like to thank H Kersten and M Kersten, for their generous support, as well as JR van Dijk and the Adessium foundation.
See Editorial commentary, p 591
Linked article 241539.
JHV and LHVdB contributed equally.
Funding Supported by the VSB fonds, The Brain Foundation of the Netherlands, Prinses Beatrix Fonds and the Catharijne Stichting.
Competing interests None.
Ethics approval Ethics approval was provided by the Medical Institutional Ethical Committee of the University Medical Centre Utrecht.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.